nodes	percent_of_prediction	percent_of_DWPC	metapath
Diphenhydramine—SLC22A2—Cisplatin—bone cancer	0.335	0.433	CbGbCtD
Diphenhydramine—CYP2B6—Cisplatin—bone cancer	0.174	0.225	CbGbCtD
Diphenhydramine—CYP2B6—Doxorubicin—bone cancer	0.116	0.151	CbGbCtD
Diphenhydramine—CYP2C9—Cisplatin—bone cancer	0.0918	0.119	CbGbCtD
Diphenhydramine—CYP2D6—Doxorubicin—bone cancer	0.0562	0.0728	CbGbCtD
Diphenhydramine—Bedaquiline—CYP3A4—bone cancer	0.00315	0.108	CrCbGaD
Diphenhydramine—Reboxetine—CYP3A4—bone cancer	0.00162	0.0555	CrCbGaD
Diphenhydramine—CYP2C19—Xenobiotics—CYP3A4—bone cancer	0.00162	0.00997	CbGpPWpGaD
Diphenhydramine—CYP2C19—Tamoxifen metabolism—CYP3A4—bone cancer	0.00156	0.00959	CbGpPWpGaD
Diphenhydramine—CYP1A2—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.00151	0.00929	CbGpPWpGaD
Diphenhydramine—CYP2D6—Xenobiotics—CYP3A4—bone cancer	0.00149	0.00917	CbGpPWpGaD
Diphenhydramine—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.00148	0.00909	CbGpPWpGaD
Diphenhydramine—CYP2B6—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.00147	0.00906	CbGpPWpGaD
Diphenhydramine—CYP2C18—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00147	0.00903	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metapathway biotransformation—CYP4V2—bone cancer	0.00144	0.00889	CbGpPWpGaD
Diphenhydramine—Oxaprozin—PTGS2—bone cancer	0.00144	0.0492	CrCbGaD
Diphenhydramine—CYP2D6—Tamoxifen metabolism—CYP3A4—bone cancer	0.00143	0.00882	CbGpPWpGaD
Diphenhydramine—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.00142	0.00874	CbGpPWpGaD
Diphenhydramine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00141	0.0087	CbGpPWpGaD
Diphenhydramine—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.0014	0.00863	CbGpPWpGaD
Diphenhydramine—CYP1A2—Estrogen metabolism—CYP3A4—bone cancer	0.00137	0.00845	CbGpPWpGaD
Diphenhydramine—CYP2D6—Metapathway biotransformation—CYP4V2—bone cancer	0.00133	0.00818	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.00132	0.00811	CbGpPWpGaD
Diphenhydramine—CYP1A2—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.00131	0.00809	CbGpPWpGaD
Diphenhydramine—PTGS1—Overview of nanoparticle effects—PTGS2—bone cancer	0.0013	0.00798	CbGpPWpGaD
Diphenhydramine—Toremifene—CYP3A4—bone cancer	0.00129	0.0441	CrCbGaD
Diphenhydramine—CYP1A2—Xenobiotics—CYP3A4—bone cancer	0.00126	0.00777	CbGpPWpGaD
Diphenhydramine—CHRM2—GPCRs, Other—GRM1—bone cancer	0.00126	0.00773	CbGpPWpGaD
Diphenhydramine—CYP1A2—Tamoxifen metabolism—CYP3A4—bone cancer	0.00121	0.00747	CbGpPWpGaD
Diphenhydramine—Alimemazine—CYP3A4—bone cancer	0.00121	0.0413	CrCbGaD
Diphenhydramine—Fenoprofen—PTGS2—bone cancer	0.00119	0.0406	CrCbGaD
Diphenhydramine—Bifonazole—CYP3A4—bone cancer	0.00116	0.0396	CrCbGaD
Diphenhydramine—CYP1A2—Metapathway biotransformation—CYP4V2—bone cancer	0.00112	0.00693	CbGpPWpGaD
Diphenhydramine—Cyclobenzaprine—CYP3A4—bone cancer	0.00111	0.0381	CrCbGaD
Diphenhydramine—Clomifene—CYP3A4—bone cancer	0.00111	0.0381	CrCbGaD
Diphenhydramine—CYP2C19—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.00111	0.00684	CbGpPWpGaD
Diphenhydramine—PTGS1—Eicosanoid Synthesis—PTGS2—bone cancer	0.00108	0.00662	CbGpPWpGaD
Diphenhydramine—Phenprocoumon—CYP3A4—bone cancer	0.00105	0.0358	CrCbGaD
Diphenhydramine—Wheezing—Cisplatin—bone cancer	0.00103	0.029	CcSEcCtD
Diphenhydramine—CYP2C18—Tryptophan metabolism—MDM2—bone cancer	0.00103	0.00633	CbGpPWpGaD
Diphenhydramine—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.00101	0.00624	CbGpPWpGaD
Diphenhydramine—CHRM2—Calcium Regulation in the Cardiac Cell—RGS1—bone cancer	0.000976	0.00601	CbGpPWpGaD
Diphenhydramine—Phenylbutazone—CYP3A4—bone cancer	0.00097	0.0332	CrCbGaD
Diphenhydramine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000965	0.00595	CbGpPWpGaD
Diphenhydramine—Phenylbutazone—PTGS2—bone cancer	0.00095	0.0325	CrCbGaD
Diphenhydramine—PTGS1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000945	0.00582	CbGpPWpGaD
Diphenhydramine—Warfarin—CYP3A4—bone cancer	0.000928	0.0318	CrCbGaD
Diphenhydramine—CYP2C18—FOXA1 transcription factor network—JUN—bone cancer	0.000926	0.0057	CbGpPWpGaD
Diphenhydramine—Carbinoxamine—CYP3A4—bone cancer	0.000915	0.0313	CrCbGaD
Diphenhydramine—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—bone cancer	0.000899	0.00554	CbGpPWpGaD
Diphenhydramine—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000889	0.00548	CbGpPWpGaD
Diphenhydramine—CHRM2—GPCRs, Other—SMO—bone cancer	0.000885	0.00545	CbGpPWpGaD
Diphenhydramine—CYP2B6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000878	0.00541	CbGpPWpGaD
Diphenhydramine—Levomethadyl Acetate—CYP3A4—bone cancer	0.000869	0.0298	CrCbGaD
Diphenhydramine—Haemolytic anaemia—Cisplatin—bone cancer	0.000852	0.024	CcSEcCtD
Diphenhydramine—Nasal congestion—Cisplatin—bone cancer	0.000845	0.0238	CcSEcCtD
Diphenhydramine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000825	0.00508	CbGpPWpGaD
Diphenhydramine—Brompheniramine—CYP3A4—bone cancer	0.000793	0.0271	CrCbGaD
Diphenhydramine—CYP2C18—Biological oxidations—CYP3A4—bone cancer	0.000779	0.0048	CbGpPWpGaD
Diphenhydramine—Chlorphenamine—CYP3A4—bone cancer	0.000778	0.0266	CrCbGaD
Diphenhydramine—CYP2C18—Metapathway biotransformation—CYP3A4—bone cancer	0.000768	0.00473	CbGpPWpGaD
Diphenhydramine—Modafinil—CYP3A4—bone cancer	0.00076	0.026	CrCbGaD
Diphenhydramine—Dextropropoxyphene—CYP3A4—bone cancer	0.000751	0.0257	CrCbGaD
Diphenhydramine—Fentanyl—CYP3A4—bone cancer	0.000743	0.0254	CrCbGaD
Diphenhydramine—Irritability—Cisplatin—bone cancer	0.000734	0.0207	CcSEcCtD
Diphenhydramine—Neuritis—Epirubicin—bone cancer	0.000729	0.0205	CcSEcCtD
Diphenhydramine—CYP2B6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000721	0.00444	CbGpPWpGaD
Diphenhydramine—HRH1—G alpha (q) signalling events—GRM1—bone cancer	0.000717	0.00442	CbGpPWpGaD
Diphenhydramine—CYP1A2—Estrogen Receptor Pathway—JUN—bone cancer	0.000711	0.00438	CbGpPWpGaD
Diphenhydramine—CHRM2—G alpha (i) signalling events—GRM4—bone cancer	0.000678	0.00418	CbGpPWpGaD
Diphenhydramine—CHRM2—G alpha (i) signalling events—RGS1—bone cancer	0.000678	0.00418	CbGpPWpGaD
Diphenhydramine—Neuritis—Doxorubicin—bone cancer	0.000675	0.019	CcSEcCtD
Diphenhydramine—Phenytoin—CYP3A4—bone cancer	0.000674	0.0231	CrCbGaD
Diphenhydramine—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000672	0.00414	CbGpPWpGaD
Diphenhydramine—CYP2C18—Biological oxidations—GSTP1—bone cancer	0.000666	0.0041	CbGpPWpGaD
Diphenhydramine—CYP2C19—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000663	0.00409	CbGpPWpGaD
Diphenhydramine—Benzphetamine—CYP3A4—bone cancer	0.000659	0.0226	CrCbGaD
Diphenhydramine—CYP2C18—Metapathway biotransformation—GSTP1—bone cancer	0.000657	0.00405	CbGpPWpGaD
Diphenhydramine—Atomoxetine—CYP3A4—bone cancer	0.000654	0.0224	CrCbGaD
Diphenhydramine—CYP1A2—Tryptophan metabolism—CYP3A4—bone cancer	0.000648	0.00399	CbGpPWpGaD
Diphenhydramine—Sweating increased—Cisplatin—bone cancer	0.000648	0.0182	CcSEcCtD
Diphenhydramine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—GRM1—bone cancer	0.000642	0.00395	CbGpPWpGaD
Diphenhydramine—SLC22A5—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.00063	0.00388	CbGpPWpGaD
Diphenhydramine—Phenoxybenzamine—CYP3A4—bone cancer	0.00063	0.0216	CrCbGaD
Diphenhydramine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000618	0.00381	CbGpPWpGaD
Diphenhydramine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000613	0.00377	CbGpPWpGaD
Diphenhydramine—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.00061	0.00376	CbGpPWpGaD
Diphenhydramine—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000605	0.00372	CbGpPWpGaD
Diphenhydramine—PTGS1—Arachidonic acid metabolism—PTGS2—bone cancer	0.000598	0.00368	CbGpPWpGaD
Diphenhydramine—Neuropathy peripheral—Cisplatin—bone cancer	0.000581	0.0164	CcSEcCtD
Diphenhydramine—CHRM2—Calcium Regulation in the Cardiac Cell—GNA11—bone cancer	0.000545	0.00336	CbGpPWpGaD
Diphenhydramine—CYP2C19—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000545	0.00336	CbGpPWpGaD
Diphenhydramine—SLC22A5—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000544	0.00335	CbGpPWpGaD
Diphenhydramine—Trimipramine—CYP3A4—bone cancer	0.000538	0.0184	CrCbGaD
Diphenhydramine—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000524	0.00323	CbGpPWpGaD
Diphenhydramine—CYP1A2—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000517	0.00318	CbGpPWpGaD
Diphenhydramine—Tamoxifen—CYP3A4—bone cancer	0.000514	0.0176	CrCbGaD
Diphenhydramine—Doxepin—CYP3A4—bone cancer	0.000512	0.0175	CrCbGaD
Diphenhydramine—Methadone—CYP3A4—bone cancer	0.00051	0.0174	CrCbGaD
Diphenhydramine—PTGS1—Biological oxidations—CYP3A4—bone cancer	0.000502	0.00309	CbGpPWpGaD
Diphenhydramine—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000501	0.00309	CbGpPWpGaD
Diphenhydramine—Orphenadrine—CYP3A4—bone cancer	0.000499	0.0171	CrCbGaD
Diphenhydramine—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000497	0.00306	CbGpPWpGaD
Diphenhydramine—Tinnitus—Cisplatin—bone cancer	0.000496	0.014	CcSEcCtD
Diphenhydramine—Photosensitivity—Methotrexate—bone cancer	0.000481	0.0135	CcSEcCtD
Diphenhydramine—CYP2C18—Metabolism—NDUFA12—bone cancer	0.000467	0.00288	CbGpPWpGaD
Diphenhydramine—HRH1—G alpha (q) signalling events—GNA11—bone cancer	0.000462	0.00285	CbGpPWpGaD
Diphenhydramine—Promazine—CYP3A4—bone cancer	0.000455	0.0156	CrCbGaD
Diphenhydramine—Photosensitivity—Epirubicin—bone cancer	0.00045	0.0127	CcSEcCtD
Diphenhydramine—Vision blurred—Cisplatin—bone cancer	0.000437	0.0123	CcSEcCtD
Diphenhydramine—Tremor—Cisplatin—bone cancer	0.000434	0.0122	CcSEcCtD
Diphenhydramine—PTGS1—Biological oxidations—GSTP1—bone cancer	0.000429	0.00264	CbGpPWpGaD
Diphenhydramine—CYP1A2—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000425	0.00261	CbGpPWpGaD
Diphenhydramine—HRH1—GPCR ligand binding—GRM4—bone cancer	0.000417	0.00257	CbGpPWpGaD
Diphenhydramine—Photosensitivity—Doxorubicin—bone cancer	0.000416	0.0117	CcSEcCtD
Diphenhydramine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	0.000413	0.00255	CbGpPWpGaD
Diphenhydramine—CHRM2—GPCR ligand binding—GRM4—bone cancer	0.000411	0.00253	CbGpPWpGaD
Diphenhydramine—Irritability—Methotrexate—bone cancer	0.000403	0.0113	CcSEcCtD
Diphenhydramine—Convulsion—Cisplatin—bone cancer	0.000401	0.0113	CcSEcCtD
Diphenhydramine—Imipramine—CYP3A4—bone cancer	0.000399	0.0136	CrCbGaD
Diphenhydramine—SLC22A2—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000396	0.00244	CbGpPWpGaD
Diphenhydramine—Amitriptyline—CYP3A4—bone cancer	0.000396	0.0136	CrCbGaD
Diphenhydramine—Diplopia—Epirubicin—bone cancer	0.000395	0.0111	CcSEcCtD
Diphenhydramine—CYP2C18—Metabolism—NT5C3A—bone cancer	0.000387	0.00238	CbGpPWpGaD
Diphenhydramine—CYP2B6—Biological oxidations—CYP3A4—bone cancer	0.000383	0.00236	CbGpPWpGaD
Diphenhydramine—PTGS1—Selenium Micronutrient Network—PTGS2—bone cancer	0.00038	0.00234	CbGpPWpGaD
Diphenhydramine—CYP2B6—Metapathway biotransformation—CYP3A4—bone cancer	0.000378	0.00233	CbGpPWpGaD
Diphenhydramine—Thrombocytopenia—Cisplatin—bone cancer	0.00037	0.0104	CcSEcCtD
Diphenhydramine—SLC22A1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.00037	0.00228	CbGpPWpGaD
Diphenhydramine—Tachycardia—Cisplatin—bone cancer	0.000369	0.0104	CcSEcCtD
Diphenhydramine—Diplopia—Doxorubicin—bone cancer	0.000366	0.0103	CcSEcCtD
Diphenhydramine—Hyperhidrosis—Cisplatin—bone cancer	0.000366	0.0103	CcSEcCtD
Diphenhydramine—HRH1—GPCR ligand binding—GRM1—bone cancer	0.000362	0.00223	CbGpPWpGaD
Diphenhydramine—Anorexia—Cisplatin—bone cancer	0.00036	0.0101	CcSEcCtD
Diphenhydramine—CHRM2—GPCR ligand binding—GRM1—bone cancer	0.000356	0.00219	CbGpPWpGaD
Diphenhydramine—Hypotension—Cisplatin—bone cancer	0.000353	0.00994	CcSEcCtD
Diphenhydramine—CYP1A2—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000349	0.00215	CbGpPWpGaD
Diphenhydramine—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	0.000345	0.00212	CbGpPWpGaD
Diphenhydramine—SLC22A2—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000342	0.00211	CbGpPWpGaD
Diphenhydramine—Dysuria—Methotrexate—bone cancer	0.000341	0.0096	CcSEcCtD
Diphenhydramine—Paraesthesia—Cisplatin—bone cancer	0.00034	0.00955	CcSEcCtD
Diphenhydramine—Photosensitivity reaction—Methotrexate—bone cancer	0.000333	0.00937	CcSEcCtD
Diphenhydramine—CYP1A2—Phase II conjugation—GSTP1—bone cancer	0.00033	0.00203	CbGpPWpGaD
Diphenhydramine—Decreased appetite—Cisplatin—bone cancer	0.000329	0.00925	CcSEcCtD
Diphenhydramine—CYP2B6—Biological oxidations—GSTP1—bone cancer	0.000328	0.00202	CbGpPWpGaD
Diphenhydramine—Drowsiness—Methotrexate—bone cancer	0.000325	0.00916	CcSEcCtD
Diphenhydramine—CYP2B6—Metapathway biotransformation—GSTP1—bone cancer	0.000323	0.00199	CbGpPWpGaD
Diphenhydramine—Dysuria—Epirubicin—bone cancer	0.000319	0.00899	CcSEcCtD
Diphenhydramine—SLC22A1—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000319	0.00196	CbGpPWpGaD
Diphenhydramine—Pollakiuria—Epirubicin—bone cancer	0.000315	0.00888	CcSEcCtD
Diphenhydramine—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	0.000314	0.00193	CbGpPWpGaD
Diphenhydramine—Photosensitivity reaction—Epirubicin—bone cancer	0.000312	0.00877	CcSEcCtD
Diphenhydramine—Feeling abnormal—Cisplatin—bone cancer	0.000312	0.00877	CcSEcCtD
Diphenhydramine—SLC22A2—Metabolism—NDUFA12—bone cancer	0.00031	0.00191	CbGpPWpGaD
Diphenhydramine—Drowsiness—Epirubicin—bone cancer	0.000304	0.00857	CcSEcCtD
Diphenhydramine—Agranulocytosis—Methotrexate—bone cancer	0.000304	0.00854	CcSEcCtD
Diphenhydramine—PTGS1—Metabolism—NDUFA12—bone cancer	0.000301	0.00185	CbGpPWpGaD
Diphenhydramine—Neuropathy peripheral—Epirubicin—bone cancer	0.000298	0.0084	CcSEcCtD
Diphenhydramine—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	0.000298	0.00183	CbGpPWpGaD
Diphenhydramine—Dysuria—Doxorubicin—bone cancer	0.000295	0.00831	CcSEcCtD
Diphenhydramine—Pollakiuria—Doxorubicin—bone cancer	0.000292	0.00821	CcSEcCtD
Diphenhydramine—CYP2C19—Biological oxidations—CYP3A4—bone cancer	0.000289	0.00178	CbGpPWpGaD
Diphenhydramine—SLC22A1—Metabolism—NDUFA12—bone cancer	0.000289	0.00178	CbGpPWpGaD
Diphenhydramine—Photosensitivity reaction—Doxorubicin—bone cancer	0.000288	0.00812	CcSEcCtD
Diphenhydramine—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	0.000287	0.00177	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	0.000285	0.00176	CbGpPWpGaD
Diphenhydramine—Agranulocytosis—Epirubicin—bone cancer	0.000284	0.008	CcSEcCtD
Diphenhydramine—Drowsiness—Doxorubicin—bone cancer	0.000282	0.00793	CcSEcCtD
Diphenhydramine—Neuropathy peripheral—Doxorubicin—bone cancer	0.000276	0.00777	CcSEcCtD
Diphenhydramine—Tinnitus—Methotrexate—bone cancer	0.000272	0.00766	CcSEcCtD
Diphenhydramine—Asthenia—Cisplatin—bone cancer	0.000271	0.00763	CcSEcCtD
Diphenhydramine—CHRM2—Regulation of Actin Cytoskeleton—BRAF—bone cancer	0.000271	0.00167	CbGpPWpGaD
Diphenhydramine—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	0.000268	0.00165	CbGpPWpGaD
Diphenhydramine—CYP2D6—Biological oxidations—CYP3A4—bone cancer	0.000266	0.00164	CbGpPWpGaD
Diphenhydramine—CYP2C9—Biological oxidations—CYP3A4—bone cancer	0.000264	0.00163	CbGpPWpGaD
Diphenhydramine—Agranulocytosis—Doxorubicin—bone cancer	0.000263	0.0074	CcSEcCtD
Diphenhydramine—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	0.000263	0.00162	CbGpPWpGaD
Diphenhydramine—Chills—Methotrexate—bone cancer	0.000262	0.00737	CcSEcCtD
Diphenhydramine—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	0.00026	0.0016	CbGpPWpGaD
Diphenhydramine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.000259	0.00159	CbGpPWpGaD
Diphenhydramine—Diarrhoea—Cisplatin—bone cancer	0.000259	0.00728	CcSEcCtD
Diphenhydramine—SLC22A2—Metabolism—NT5C3A—bone cancer	0.000257	0.00158	CbGpPWpGaD
Diphenhydramine—HRH1—GPCR ligand binding—SMO—bone cancer	0.000255	0.00157	CbGpPWpGaD
Diphenhydramine—Tinnitus—Epirubicin—bone cancer	0.000255	0.00717	CcSEcCtD
Diphenhydramine—SLC22A2—Transmission across Chemical Synapses—BRAF—bone cancer	0.000251	0.00155	CbGpPWpGaD
Diphenhydramine—CHRM2—GPCR ligand binding—SMO—bone cancer	0.000251	0.00154	CbGpPWpGaD
Diphenhydramine—PTGS1—Metabolism—NT5C3A—bone cancer	0.000249	0.00154	CbGpPWpGaD
Diphenhydramine—CYP2C19—Biological oxidations—GSTP1—bone cancer	0.000248	0.00152	CbGpPWpGaD
Diphenhydramine—Chills—Epirubicin—bone cancer	0.000245	0.0069	CcSEcCtD
Diphenhydramine—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	0.000244	0.0015	CbGpPWpGaD
Diphenhydramine—Vomiting—Cisplatin—bone cancer	0.00024	0.00677	CcSEcCtD
Diphenhydramine—Vision blurred—Methotrexate—bone cancer	0.00024	0.00674	CcSEcCtD
Diphenhydramine—SLC22A1—Metabolism—NT5C3A—bone cancer	0.000239	0.00147	CbGpPWpGaD
Diphenhydramine—Rash—Cisplatin—bone cancer	0.000238	0.00671	CcSEcCtD
Diphenhydramine—Dermatitis—Cisplatin—bone cancer	0.000238	0.0067	CcSEcCtD
Diphenhydramine—HRH1—GPCR downstream signaling—GRM4—bone cancer	0.000236	0.00145	CbGpPWpGaD
Diphenhydramine—HRH1—GPCR downstream signaling—RGS1—bone cancer	0.000236	0.00145	CbGpPWpGaD
Diphenhydramine—Tinnitus—Doxorubicin—bone cancer	0.000236	0.00664	CcSEcCtD
Diphenhydramine—SLC22A1—Transmission across Chemical Synapses—BRAF—bone cancer	0.000234	0.00144	CbGpPWpGaD
Diphenhydramine—Tension—Epirubicin—bone cancer	0.000233	0.00657	CcSEcCtD
Diphenhydramine—CHRM2—GPCR downstream signaling—RGS1—bone cancer	0.000232	0.00143	CbGpPWpGaD
Diphenhydramine—CHRM2—GPCR downstream signaling—GRM4—bone cancer	0.000232	0.00143	CbGpPWpGaD
Diphenhydramine—Nervousness—Epirubicin—bone cancer	0.000231	0.0065	CcSEcCtD
Diphenhydramine—CYP2B6—Metabolism—NDUFA12—bone cancer	0.00023	0.00141	CbGpPWpGaD
Diphenhydramine—Vertigo—Methotrexate—bone cancer	0.000228	0.00643	CcSEcCtD
Diphenhydramine—CYP2D6—Biological oxidations—GSTP1—bone cancer	0.000228	0.0014	CbGpPWpGaD
Diphenhydramine—Chills—Doxorubicin—bone cancer	0.000227	0.00639	CcSEcCtD
Diphenhydramine—CYP2C9—Biological oxidations—GSTP1—bone cancer	0.000226	0.00139	CbGpPWpGaD
Diphenhydramine—CYP1A2—Biological oxidations—CYP3A4—bone cancer	0.000226	0.00139	CbGpPWpGaD
Diphenhydramine—Nausea—Cisplatin—bone cancer	0.000225	0.00632	CcSEcCtD
Diphenhydramine—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	0.000225	0.00138	CbGpPWpGaD
Diphenhydramine—Vision blurred—Epirubicin—bone cancer	0.000224	0.00631	CcSEcCtD
Diphenhydramine—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	0.000223	0.00137	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	0.000222	0.00137	CbGpPWpGaD
Diphenhydramine—Convulsion—Methotrexate—bone cancer	0.00022	0.0062	CcSEcCtD
Diphenhydramine—Agitation—Epirubicin—bone cancer	0.000219	0.00615	CcSEcCtD
Diphenhydramine—Tension—Doxorubicin—bone cancer	0.000216	0.00608	CcSEcCtD
Diphenhydramine—HRH1—Signaling by GPCR—GRM4—bone cancer	0.000214	0.00132	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling by GPCR—RGS1—bone cancer	0.000214	0.00132	CbGpPWpGaD
Diphenhydramine—Nervousness—Doxorubicin—bone cancer	0.000214	0.00602	CcSEcCtD
Diphenhydramine—Vertigo—Epirubicin—bone cancer	0.000214	0.00602	CcSEcCtD
Diphenhydramine—CHRM2—Signaling by GPCR—RGS1—bone cancer	0.000211	0.0013	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling by GPCR—GRM4—bone cancer	0.000211	0.0013	CbGpPWpGaD
Diphenhydramine—SLC22A2—Transmission across Chemical Synapses—MDM2—bone cancer	0.000211	0.0013	CbGpPWpGaD
Diphenhydramine—Palpitations—Epirubicin—bone cancer	0.00021	0.00592	CcSEcCtD
Diphenhydramine—Confusional state—Methotrexate—bone cancer	0.000209	0.00589	CcSEcCtD
Diphenhydramine—Vision blurred—Doxorubicin—bone cancer	0.000207	0.00584	CcSEcCtD
Diphenhydramine—Convulsion—Epirubicin—bone cancer	0.000206	0.0058	CcSEcCtD
Diphenhydramine—HRH1—GPCR downstream signaling—GRM1—bone cancer	0.000204	0.00126	CbGpPWpGaD
Diphenhydramine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	0.000203	0.00125	CbGpPWpGaD
Diphenhydramine—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	0.000203	0.00125	CbGpPWpGaD
Diphenhydramine—Thrombocytopenia—Methotrexate—bone cancer	0.000203	0.00572	CcSEcCtD
Diphenhydramine—Agitation—Doxorubicin—bone cancer	0.000202	0.00569	CcSEcCtD
Diphenhydramine—CHRM2—GPCR downstream signaling—GRM1—bone cancer	0.000201	0.00124	CbGpPWpGaD
Diphenhydramine—Hyperhidrosis—Methotrexate—bone cancer	0.000201	0.00564	CcSEcCtD
Diphenhydramine—Dry mouth—Epirubicin—bone cancer	0.000198	0.00557	CcSEcCtD
Diphenhydramine—Vertigo—Doxorubicin—bone cancer	0.000198	0.00557	CcSEcCtD
Diphenhydramine—Anorexia—Methotrexate—bone cancer	0.000198	0.00557	CcSEcCtD
Diphenhydramine—SLC22A1—Transmission across Chemical Synapses—MDM2—bone cancer	0.000196	0.00121	CbGpPWpGaD
Diphenhydramine—Confusional state—Epirubicin—bone cancer	0.000196	0.00551	CcSEcCtD
Diphenhydramine—Palpitations—Doxorubicin—bone cancer	0.000195	0.00547	CcSEcCtD
Diphenhydramine—Hypotension—Methotrexate—bone cancer	0.000194	0.00546	CcSEcCtD
Diphenhydramine—CYP1A2—Biological oxidations—GSTP1—bone cancer	0.000193	0.00119	CbGpPWpGaD
Diphenhydramine—SLC22A2—Neuronal System—BRAF—bone cancer	0.000193	0.00119	CbGpPWpGaD
Diphenhydramine—Convulsion—Doxorubicin—bone cancer	0.000191	0.00537	CcSEcCtD
Diphenhydramine—CHRM2—SIDS Susceptibility Pathways—JUN—bone cancer	0.00019	0.00117	CbGpPWpGaD
Diphenhydramine—CYP2B6—Metabolism—NT5C3A—bone cancer	0.00019	0.00117	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	0.00019	0.00117	CbGpPWpGaD
Diphenhydramine—Thrombocytopenia—Epirubicin—bone cancer	0.00019	0.00535	CcSEcCtD
Diphenhydramine—Tachycardia—Epirubicin—bone cancer	0.00019	0.00533	CcSEcCtD
Diphenhydramine—Hyperhidrosis—Epirubicin—bone cancer	0.000188	0.00528	CcSEcCtD
Diphenhydramine—Insomnia—Methotrexate—bone cancer	0.000188	0.00528	CcSEcCtD
Diphenhydramine—Paraesthesia—Methotrexate—bone cancer	0.000186	0.00524	CcSEcCtD
Diphenhydramine—HRH1—Signaling by GPCR—GRM1—bone cancer	0.000186	0.00114	CbGpPWpGaD
Diphenhydramine—Anorexia—Epirubicin—bone cancer	0.000185	0.00521	CcSEcCtD
Diphenhydramine—Somnolence—Methotrexate—bone cancer	0.000184	0.00519	CcSEcCtD
Diphenhydramine—Dry mouth—Doxorubicin—bone cancer	0.000183	0.00516	CcSEcCtD
Diphenhydramine—CHRM2—Signaling by GPCR—GRM1—bone cancer	0.000183	0.00113	CbGpPWpGaD
Diphenhydramine—Dyspepsia—Methotrexate—bone cancer	0.000183	0.00514	CcSEcCtD
Diphenhydramine—Hypotension—Epirubicin—bone cancer	0.000181	0.00511	CcSEcCtD
Diphenhydramine—Confusional state—Doxorubicin—bone cancer	0.000181	0.0051	CcSEcCtD
Diphenhydramine—Decreased appetite—Methotrexate—bone cancer	0.00018	0.00508	CcSEcCtD
Diphenhydramine—SLC22A1—Neuronal System—BRAF—bone cancer	0.00018	0.00111	CbGpPWpGaD
Diphenhydramine—Fatigue—Methotrexate—bone cancer	0.000179	0.00503	CcSEcCtD
Diphenhydramine—Thrombocytopenia—Doxorubicin—bone cancer	0.000176	0.00495	CcSEcCtD
Diphenhydramine—Insomnia—Epirubicin—bone cancer	0.000176	0.00494	CcSEcCtD
Diphenhydramine—Tachycardia—Doxorubicin—bone cancer	0.000175	0.00493	CcSEcCtD
Diphenhydramine—Paraesthesia—Epirubicin—bone cancer	0.000174	0.00491	CcSEcCtD
Diphenhydramine—Hyperhidrosis—Doxorubicin—bone cancer	0.000174	0.00489	CcSEcCtD
Diphenhydramine—CYP2C19—Metabolism—NDUFA12—bone cancer	0.000173	0.00107	CbGpPWpGaD
Diphenhydramine—Somnolence—Epirubicin—bone cancer	0.000173	0.00486	CcSEcCtD
Diphenhydramine—Anorexia—Doxorubicin—bone cancer	0.000171	0.00482	CcSEcCtD
Diphenhydramine—Feeling abnormal—Methotrexate—bone cancer	0.000171	0.00481	CcSEcCtD
Diphenhydramine—Dyspepsia—Epirubicin—bone cancer	0.000171	0.00481	CcSEcCtD
Diphenhydramine—CYP2C18—Metabolism—ENO2—bone cancer	0.000169	0.00104	CbGpPWpGaD
Diphenhydramine—Decreased appetite—Epirubicin—bone cancer	0.000169	0.00475	CcSEcCtD
Diphenhydramine—Hypotension—Doxorubicin—bone cancer	0.000168	0.00472	CcSEcCtD
Diphenhydramine—Fatigue—Epirubicin—bone cancer	0.000167	0.00471	CcSEcCtD
Diphenhydramine—Constipation—Epirubicin—bone cancer	0.000166	0.00467	CcSEcCtD
Diphenhydramine—Urticaria—Methotrexate—bone cancer	0.000165	0.00464	CcSEcCtD
Diphenhydramine—Insomnia—Doxorubicin—bone cancer	0.000163	0.00457	CcSEcCtD
Diphenhydramine—SLC22A2—Neuronal System—MDM2—bone cancer	0.000161	0.000994	CbGpPWpGaD
Diphenhydramine—Paraesthesia—Doxorubicin—bone cancer	0.000161	0.00454	CcSEcCtD
Diphenhydramine—Feeling abnormal—Epirubicin—bone cancer	0.00016	0.0045	CcSEcCtD
Diphenhydramine—Somnolence—Doxorubicin—bone cancer	0.00016	0.00449	CcSEcCtD
Diphenhydramine—CYP2D6—Metabolism—NDUFA12—bone cancer	0.00016	0.000983	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism—NDUFA12—bone cancer	0.000158	0.000974	CbGpPWpGaD
Diphenhydramine—Dyspepsia—Doxorubicin—bone cancer	0.000158	0.00445	CcSEcCtD
Diphenhydramine—CYP2C18—Metabolism—DHFR—bone cancer	0.000157	0.000968	CbGpPWpGaD
Diphenhydramine—Decreased appetite—Doxorubicin—bone cancer	0.000156	0.0044	CcSEcCtD
Diphenhydramine—CHRM2—Regulation of Actin Cytoskeleton—EGFR—bone cancer	0.000155	0.000957	CbGpPWpGaD
Diphenhydramine—Fatigue—Doxorubicin—bone cancer	0.000155	0.00436	CcSEcCtD
Diphenhydramine—Urticaria—Epirubicin—bone cancer	0.000154	0.00434	CcSEcCtD
Diphenhydramine—Constipation—Doxorubicin—bone cancer	0.000154	0.00432	CcSEcCtD
Diphenhydramine—SLC22A1—Neuronal System—MDM2—bone cancer	0.00015	0.000927	CbGpPWpGaD
Diphenhydramine—Asthenia—Methotrexate—bone cancer	0.000149	0.00419	CcSEcCtD
Diphenhydramine—Feeling abnormal—Doxorubicin—bone cancer	0.000148	0.00417	CcSEcCtD
Diphenhydramine—CYP2C18—Metabolism—GNA11—bone cancer	0.000147	0.000905	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism—NT5C3A—bone cancer	0.000144	0.000885	CbGpPWpGaD
Diphenhydramine—Urticaria—Doxorubicin—bone cancer	0.000143	0.00402	CcSEcCtD
Diphenhydramine—Diarrhoea—Methotrexate—bone cancer	0.000142	0.004	CcSEcCtD
Diphenhydramine—Asthenia—Epirubicin—bone cancer	0.000139	0.00392	CcSEcCtD
Diphenhydramine—Dizziness—Methotrexate—bone cancer	0.000137	0.00386	CcSEcCtD
Diphenhydramine—CYP1A2—Metabolism—NDUFA12—bone cancer	0.000135	0.000833	CbGpPWpGaD
Diphenhydramine—CYP2C18—Metabolism—CYP3A4—bone cancer	0.000133	0.000821	CbGpPWpGaD
Diphenhydramine—Diarrhoea—Epirubicin—bone cancer	0.000133	0.00374	CcSEcCtD
Diphenhydramine—CYP2D6—Metabolism—NT5C3A—bone cancer	0.000132	0.000814	CbGpPWpGaD
Diphenhydramine—Vomiting—Methotrexate—bone cancer	0.000132	0.00371	CcSEcCtD
Diphenhydramine—HRH1—GPCR downstream signaling—GNA11—bone cancer	0.000132	0.000811	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism—NT5C3A—bone cancer	0.000131	0.000807	CbGpPWpGaD
Diphenhydramine—Rash—Methotrexate—bone cancer	0.000131	0.00368	CcSEcCtD
Diphenhydramine—HRH1—Signaling by GPCR—SMO—bone cancer	0.000131	0.000806	CbGpPWpGaD
Diphenhydramine—Dermatitis—Methotrexate—bone cancer	0.000131	0.00368	CcSEcCtD
Diphenhydramine—Headache—Methotrexate—bone cancer	0.00013	0.00366	CcSEcCtD
Diphenhydramine—CHRM2—GPCR downstream signaling—GNA11—bone cancer	0.00013	0.000798	CbGpPWpGaD
Diphenhydramine—Asthenia—Doxorubicin—bone cancer	0.000129	0.00363	CcSEcCtD
Diphenhydramine—CHRM2—Signaling by GPCR—SMO—bone cancer	0.000129	0.000793	CbGpPWpGaD
Diphenhydramine—Dizziness—Epirubicin—bone cancer	0.000128	0.00361	CcSEcCtD
Diphenhydramine—HRH1—Signaling Pathways—RGS1—bone cancer	0.000126	0.000779	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—GRM4—bone cancer	0.000126	0.000779	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—GRM4—bone cancer	0.000124	0.000767	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—RGS1—bone cancer	0.000124	0.000767	CbGpPWpGaD
Diphenhydramine—Vomiting—Epirubicin—bone cancer	0.000123	0.00347	CcSEcCtD
Diphenhydramine—Nausea—Methotrexate—bone cancer	0.000123	0.00347	CcSEcCtD
Diphenhydramine—Diarrhoea—Doxorubicin—bone cancer	0.000123	0.00346	CcSEcCtD
Diphenhydramine—Rash—Epirubicin—bone cancer	0.000122	0.00345	CcSEcCtD
Diphenhydramine—Dermatitis—Epirubicin—bone cancer	0.000122	0.00344	CcSEcCtD
Diphenhydramine—Headache—Epirubicin—bone cancer	0.000122	0.00342	CcSEcCtD
Diphenhydramine—HRH1—Signaling by GPCR—GNA11—bone cancer	0.00012	0.000737	CbGpPWpGaD
Diphenhydramine—HRH1—GPCR downstream signaling—IL3—bone cancer	0.000119	0.000736	CbGpPWpGaD
Diphenhydramine—Dizziness—Doxorubicin—bone cancer	0.000119	0.00334	CcSEcCtD
Diphenhydramine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	0.000118	0.000725	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling by GPCR—GNA11—bone cancer	0.000118	0.000725	CbGpPWpGaD
Diphenhydramine—CHRM2—GPCR downstream signaling—IL3—bone cancer	0.000118	0.000724	CbGpPWpGaD
Diphenhydramine—Nausea—Epirubicin—bone cancer	0.000115	0.00325	CcSEcCtD
Diphenhydramine—Vomiting—Doxorubicin—bone cancer	0.000114	0.00321	CcSEcCtD
Diphenhydramine—CYP2C18—Metabolism—GSTP1—bone cancer	0.000114	0.000702	CbGpPWpGaD
Diphenhydramine—Rash—Doxorubicin—bone cancer	0.000113	0.00319	CcSEcCtD
Diphenhydramine—Dermatitis—Doxorubicin—bone cancer	0.000113	0.00318	CcSEcCtD
Diphenhydramine—Headache—Doxorubicin—bone cancer	0.000113	0.00317	CcSEcCtD
Diphenhydramine—SLC22A2—Metabolism—ENO2—bone cancer	0.000113	0.000693	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism—NT5C3A—bone cancer	0.000112	0.00069	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—GRM1—bone cancer	0.00011	0.000675	CbGpPWpGaD
Diphenhydramine—PTGS1—Metabolism—ENO2—bone cancer	0.000109	0.000673	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling by GPCR—IL3—bone cancer	0.000108	0.000668	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—GRM1—bone cancer	0.000108	0.000665	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling by GPCR—IL3—bone cancer	0.000107	0.000657	CbGpPWpGaD
Diphenhydramine—Nausea—Doxorubicin—bone cancer	0.000107	0.003	CcSEcCtD
Diphenhydramine—SLC22A1—Metabolism—ENO2—bone cancer	0.000105	0.000646	CbGpPWpGaD
Diphenhydramine—SLC22A2—Metabolism—DHFR—bone cancer	0.000104	0.000643	CbGpPWpGaD
Diphenhydramine—PTGS1—Metabolism—DHFR—bone cancer	0.000101	0.000624	CbGpPWpGaD
Diphenhydramine—SLC22A2—Metabolism—GNA11—bone cancer	9.75e-05	0.000601	CbGpPWpGaD
Diphenhydramine—SLC22A1—Metabolism—DHFR—bone cancer	9.73e-05	0.000599	CbGpPWpGaD
Diphenhydramine—PTGS1—Metabolism—GNA11—bone cancer	9.47e-05	0.000583	CbGpPWpGaD
Diphenhydramine—SLC22A1—Metabolism—GNA11—bone cancer	9.09e-05	0.00056	CbGpPWpGaD
Diphenhydramine—SLC22A2—Metabolism—CYP3A4—bone cancer	8.84e-05	0.000545	CbGpPWpGaD
Diphenhydramine—PTGS1—Metabolism—CYP3A4—bone cancer	8.59e-05	0.000529	CbGpPWpGaD
Diphenhydramine—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	8.54e-05	0.000526	CbGpPWpGaD
Diphenhydramine—CYP2B6—Metabolism—ENO2—bone cancer	8.33e-05	0.000513	CbGpPWpGaD
Diphenhydramine—SLC22A1—Metabolism—CYP3A4—bone cancer	8.24e-05	0.000508	CbGpPWpGaD
Diphenhydramine—CYP2B6—Metabolism—DHFR—bone cancer	7.73e-05	0.000476	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—SMO—bone cancer	7.73e-05	0.000476	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—SMO—bone cancer	7.6e-05	0.000468	CbGpPWpGaD
Diphenhydramine—SLC22A2—Metabolism—GSTP1—bone cancer	7.56e-05	0.000466	CbGpPWpGaD
Diphenhydramine—PTGS1—Metabolism—GSTP1—bone cancer	7.34e-05	0.000452	CbGpPWpGaD
Diphenhydramine—CYP2B6—Metabolism—GNA11—bone cancer	7.22e-05	0.000445	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—GNA11—bone cancer	7.07e-05	0.000435	CbGpPWpGaD
Diphenhydramine—SLC22A1—Metabolism—GSTP1—bone cancer	7.05e-05	0.000434	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—GNA11—bone cancer	6.95e-05	0.000428	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—ATF1—bone cancer	6.57e-05	0.000405	CbGpPWpGaD
Diphenhydramine—CYP2B6—Metabolism—CYP3A4—bone cancer	6.55e-05	0.000403	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—ATF1—bone cancer	6.47e-05	0.000398	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—IL3—bone cancer	6.41e-05	0.000395	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—IL3—bone cancer	6.3e-05	0.000388	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism—ENO2—bone cancer	6.3e-05	0.000388	CbGpPWpGaD
Diphenhydramine—CYP2C18—Metabolism—PTGS2—bone cancer	5.9e-05	0.000364	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism—DHFR—bone cancer	5.84e-05	0.00036	CbGpPWpGaD
Diphenhydramine—CYP2D6—Metabolism—ENO2—bone cancer	5.79e-05	0.000357	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism—ENO2—bone cancer	5.74e-05	0.000354	CbGpPWpGaD
Diphenhydramine—CYP2B6—Metabolism—GSTP1—bone cancer	5.6e-05	0.000345	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—TGFBR2—bone cancer	5.48e-05	0.000338	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism—GNA11—bone cancer	5.46e-05	0.000336	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—TGFBR2—bone cancer	5.39e-05	0.000332	CbGpPWpGaD
Diphenhydramine—CYP2D6—Metabolism—DHFR—bone cancer	5.37e-05	0.000331	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism—DHFR—bone cancer	5.33e-05	0.000328	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—IGF1R—bone cancer	5.16e-05	0.000318	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—IGF1R—bone cancer	5.07e-05	0.000312	CbGpPWpGaD
Diphenhydramine—CYP2D6—Metabolism—GNA11—bone cancer	5.02e-05	0.000309	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism—GNA11—bone cancer	4.98e-05	0.000307	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism—CYP3A4—bone cancer	4.95e-05	0.000305	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	4.92e-05	0.000303	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism—ENO2—bone cancer	4.91e-05	0.000302	CbGpPWpGaD
Diphenhydramine—CYP2D6—Metabolism—CYP3A4—bone cancer	4.55e-05	0.00028	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism—DHFR—bone cancer	4.55e-05	0.00028	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism—CYP3A4—bone cancer	4.51e-05	0.000278	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	4.49e-05	0.000277	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism—GNA11—bone cancer	4.25e-05	0.000262	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism—GSTP1—bone cancer	4.23e-05	0.000261	CbGpPWpGaD
Diphenhydramine—SLC22A2—Metabolism—PTGS2—bone cancer	3.92e-05	0.000241	CbGpPWpGaD
Diphenhydramine—CYP2D6—Metabolism—GSTP1—bone cancer	3.89e-05	0.00024	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism—GSTP1—bone cancer	3.86e-05	0.000238	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism—CYP3A4—bone cancer	3.86e-05	0.000238	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	3.84e-05	0.000236	CbGpPWpGaD
Diphenhydramine—PTGS1—Metabolism—PTGS2—bone cancer	3.8e-05	0.000234	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—KIT—bone cancer	3.74e-05	0.00023	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—KIT—bone cancer	3.68e-05	0.000227	CbGpPWpGaD
Diphenhydramine—SLC22A1—Metabolism—PTGS2—bone cancer	3.65e-05	0.000225	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—BRAF—bone cancer	3.51e-05	0.000216	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—BRAF—bone cancer	3.46e-05	0.000213	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling by GPCR—EGFR—bone cancer	3.41e-05	0.00021	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling by GPCR—EGFR—bone cancer	3.35e-05	0.000206	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism—GSTP1—bone cancer	3.3e-05	0.000203	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—MDM2—bone cancer	2.94e-05	0.000181	CbGpPWpGaD
Diphenhydramine—CYP2B6—Metabolism—PTGS2—bone cancer	2.9e-05	0.000179	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—MDM2—bone cancer	2.9e-05	0.000178	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—JUN—bone cancer	2.56e-05	0.000158	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—JUN—bone cancer	2.52e-05	0.000155	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—MMP9—bone cancer	2.49e-05	0.000153	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—MMP9—bone cancer	2.45e-05	0.000151	CbGpPWpGaD
Diphenhydramine—CYP2C19—Metabolism—PTGS2—bone cancer	2.19e-05	0.000135	CbGpPWpGaD
Diphenhydramine—CYP2D6—Metabolism—PTGS2—bone cancer	2.02e-05	0.000124	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—EGFR—bone cancer	2.01e-05	0.000124	CbGpPWpGaD
Diphenhydramine—CYP2C9—Metabolism—PTGS2—bone cancer	2e-05	0.000123	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—EGFR—bone cancer	1.98e-05	0.000122	CbGpPWpGaD
Diphenhydramine—CYP1A2—Metabolism—PTGS2—bone cancer	1.71e-05	0.000105	CbGpPWpGaD
Diphenhydramine—HRH1—Signaling Pathways—TP53—bone cancer	1.69e-05	0.000104	CbGpPWpGaD
Diphenhydramine—CHRM2—Signaling Pathways—TP53—bone cancer	1.66e-05	0.000102	CbGpPWpGaD
